NantKwest (NK) IPO Prices at $25, Above Expected Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- AI warnings knock Nasdaq futures, pressure tech stocks
- AI-linked stocks slump after top lab CEOs call for slowing technology's development
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- 'No panic anywhere' may be the problem, BofA strategists warn
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
NantKwest (NK) Gains for Second Session Following Strong IPO
July 29, 2015 11:28 AM EDTNantKwest (Nasdaq: NK) is trading higher for the second session following Tuesday's robust IPO.
Shares of NantKwest are up well over 4 percent. Action comes as NantKwest priced its 8.28 million common stock IPO at $25 per share and opened at $37 yesterday. Shares ended up 38.6 percent higher.
... MoreNantKwest (NK) IPO Opens Up 48%
July 28, 2015 10:38 AM EDTToday's IPO for NantKwest (NASDAQ: NK) opened for trading at $37 after pricing 8,288,000 shares of its common stock at a price to the public of $25 per share, above the expected $20-$23 range. The offering size was raised from 7,000,000 shares.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray are acting as joint book-running managers for the offering, and MLV & Co. LLC is acting as co-manager.
NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat... More
